These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 18644069)

  • 1. Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat.
    Hotta N; Kawamori R; Atsumi Y; Baba M; Kishikawa H; Nakamura J; Oikawa S; Yamada N; Yasuda H; Shigeta Y;
    Diabet Med; 2008 Jul; 25(7):818-25. PubMed ID: 18644069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial.
    Hotta N; Akanuma Y; Kawamori R; Matsuoka K; Oka Y; Shichiri M; Toyota T; Nakashima M; Yoshimura I; Sakamoto N; Shigeta Y
    Diabetes Care; 2006 Jul; 29(7):1538-44. PubMed ID: 16801576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
    Hotta N; Kawamori R; Fukuda M; Shigeta Y;
    Diabet Med; 2012 Dec; 29(12):1529-33. PubMed ID: 22507139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epalrestat. A review of its pharmacology, and therapeutic potential in late-onset complications of diabetes mellitus.
    Steele JW; Faulds D; Goa KL
    Drugs Aging; 1993; 3(6):532-55. PubMed ID: 8312678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients.
    Hamada Y; Nakamura J; Naruse K; Komori T; Kato K; Kasuya Y; Nagai R; Horiuchi S; Hotta N
    Diabetes Care; 2000 Oct; 23(10):1539-44. PubMed ID: 11023149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.
    Ramirez MA; Borja NL
    Pharmacotherapy; 2008 May; 28(5):646-55. PubMed ID: 18447661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy.
    Nakayama M; Nakamura J; Hamada Y; Chaya S; Mizubayashi R; Yasuda Y; Kamiya H; Koh N; Hotta N
    Diabetes Care; 2001 Jun; 24(6):1093-8. PubMed ID: 11375376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis.
    Okamoto H; Nomura M; Nakaya Y; Uehara K; Saito K; Kimura M; Chikamori K; Ito S
    Intern Med; 2003 Aug; 42(8):655-64. PubMed ID: 12924487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A long-term effect of epalrestat on motor conduction velocity of diabetic patients: ARI-Diabetes Complications Trial (ADCT).
    Matsuoka K; Sakamoto N; Akanuma Y; Hotta N; Shichiri M; Toyota T; Oka Y; Kawamori R; Shigeta Y;
    Diabetes Res Clin Pract; 2007 Sep; 77 Suppl 1():S263-8. PubMed ID: 17599629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical efficacy of epalrestat combined with α-lipoic acid in diabetic peripheral neuropathy: Protocol for a systematic review and meta-analysis.
    Wang X; Lin H; Xu S; Jin Y; Zhang R
    Medicine (Baltimore); 2018 Feb; 97(6):e9828. PubMed ID: 29419686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(ɛ)-carboxymethyl lysine.
    Kawai T; Takei I; Tokui M; Funae O; Miyamoto K; Tabata M; Hirata T; Saruta T; Shimada A; Itoh H
    J Diabetes Complications; 2010; 24(6):424-32. PubMed ID: 19716319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of 24 weeks of treatment with epalrestat, an aldose reductase inhibitor, on peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus.
    Uchida K; Kigoshi T; Nakano S; Ishii T; Kitazawa M; Morimoto S
    Clin Ther; 1995; 17(3):460-6. PubMed ID: 7585850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldose reductase inhibition alters nodal Na+ currents and nerve conduction in human diabetics.
    Misawa S; Kuwabara S; Kanai K; Tamura N; Nakata M; Sawai S; Yagui K; Hattori T
    Neurology; 2006 May; 66(10):1545-9. PubMed ID: 16717216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan.
    Hotta N; Sakamoto N; Shigeta Y; Kikkawa R; Goto Y
    J Diabetes Complications; 1996; 10(3):168-72. PubMed ID: 8807467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy.
    Ando H; Takamura T; Nagai Y; Kaneko S;
    J Diabetes Complications; 2006; 20(6):367-70. PubMed ID: 17070440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement].
    Shimada H; Miki T; Kyogoku I; Kawagishi T; Inaba M; Okuno Y; Nishizawa Y; Morii H
    No To Shinkei; 1998 Sep; 50(9):817-20. PubMed ID: 9789304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG.
    Iyer S; Sam FS; DiPrimio N; Preston G; Verheijen J; Murthy K; Parton Z; Tsang H; Lao J; Morava E; Perlstein EO
    Dis Model Mech; 2019 Nov; 12(11):. PubMed ID: 31636082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effect of epalrestat on cardiac autonomic neuropathy in subjects with non-insulin dependent diabetes mellitus.
    Ikeda T; Iwata K; Tanaka Y
    Diabetes Res Clin Pract; 1999 Mar; 43(3):193-8. PubMed ID: 10369429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. I-123 MIBG cardiac imaging in diabetic neuropathy before and after epalrestat therapy.
    Utsunomiya K; Narabayashi I; Nakatani Y; Tamura K; Onishi S
    Clin Nucl Med; 1999 Jun; 24(6):418-20. PubMed ID: 10361937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Examination of questionnaires regarding diabetic peripheral neuropathy in epalrestat-treated patients and their usefulness in the treatment of the patients during the treatment course].
    Ito A; Ishii-Nozawa R; Ibuki C; Atarashi H; Kataoka H; Takeuchi K
    Yakugaku Zasshi; 2009 Oct; 129(10):1239-47. PubMed ID: 19797880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.